tant prognostic factor, 51, 61, 65 as is surgical reduction of the tumor. Hence, quantitative evaluation of the extent of resection is mandatory when analyzing the role of surgery.
3
Although data on pre-and postoperative sizes assessed on MRI are essential, only a few studies have reported them in large nonselected populations with GIIGs. Here, we report on a series of 1097 cases for which the initial tumor size and extent of resection could be evaluated on MRI. We analyzed spontaneous and therapeutic prognostic factors, with a special emphasis on the role of surgery. Indeed, as long as prospective randomized trials are nearly impossible to perform and could raise ethical issues, large multicenter studies of consecutive cases are probably the best way to improve our understanding of the role of surgery in GIIGs.
Methods

Case Selection
Cases selected for this study were extracted from a database containing more than 1500 consecutive cases of GIIGs that had been collected retrospectively since January 1985 and prospectively since 1996 by a French multicenter and multidisciplinary study group (Réseau d'Étude des Gliomes [REG] ) focusing on GIIGs from January 1985 up to December 2007. Six centers of a network represented the main contributors to the study, and each applied a different therapeutic attitude along the time span covered by this study. To be included in our analysis, cases collected from January 1985 up to December 2007 had to fulfill the following criteria: patient age ≥ 18 years at diagnosis, histological diagnosis of GIIG (WHO classification), and tumor size quantification at diagnosis (or treatment) and after initial surgery. Exclusion criteria were as follows: an originally deep-seated lesion (thalamus or intraventricular), ependymal or gemistocytic astrocytoma, Grade I glioma, or gliomatosis. 37 
Data Collection
Clinical and radiological examination data were retrospectively recovered for the 266 cases encountered before 1996 (24.2% of total cases) and then prospectively collected.
Clinical data included patient age, sex, symptomatology (epilepsy, deficit, headache/intracranial hypertension, and KPS score/WHO Performance Status). Imaging data included T1-weighted, T2-weighted, or FLAIR sequences (signal homogeneity, delineation, mass effect, or cyst), tumor location, and tumor volume. Volumetric evaluation was performed by the same observer (L.C.) using the ellipsoid approximation. 68 Tumors were diagnosed according to WHO guidelines. A random pathological review (by M.K.) of more than one-third of the cases was completed. Only 1.2% of the GIIGs were upgraded to a higher tumor grade, and none were discarded for a nonglioma diagnosis.
Concerning treatment, the following data were recorded: extent of surgery (using both the percentage of tumor resected and the residual tumor volume after surgery), type of radiotherapy (modality and dose), and chemotherapeutic regimen. Other variables, such as Ki 67 index, growth rate of mean diameter, and 1p/19q and p53 status, were known in only 30% of the cases and consequently were not analyzed in the present study.
Tumor Evolution
Collected data concerning eventual tumor recurrence were as follows: delay since first treatment, histological grade, symptomatology, extent of resection, type of radiotherapy, and chemotherapeutic regimen. Low-grade progression was considered to exist when histologically proven and/or, in the case of tumor growth, with no other modification of MRI tumor aspects. Malignant transformation was considered to exist when new contrast enhancement appeared or progressed if it was originally present 10, 21, 40, 65 or when histologically proven. Among the cases of malignant progression, we distinguished anaplastic (Grade III) gliomas and intermediate forms (GIIG with microfoci of anaplasia). 15 We could not consider actual progression-free survival since radiological follow-up was not uniform among all cases in this series, and because GIIGs in adults are known to show constant growth in the absence of treatment 10, 21, 39, 48, 49, 55, 56 or after surgery.
42,56
Consequently, we studied only the time to treated recurrence (either low-grade or anaplastic) and survival.
Statistical Analysis
For descriptive statistics we used numbers and percentages for qualitative variables and medians and ranges for quantitative ones. Most quantitative variables were recorded as qualitative ones. The main study considered posttreatment survival, with survival function estimated using the Kaplan-Meier method. To assess prognostic factors, univariate analysis was performed with log-rank tests for qualitative variables and univariate Cox models for quantitative ones. Factors that were significant on univariate analysis (p ≤ 0.1) were entered as candidate variables in the multivariate Cox proportional hazard regression model analysis, which comprised all principal prognostic factors suggested in the literature. Multivariate analysis was performed in a stepwise (ascending and descending) manner for covariate selection. Two-sided p values < 0.05 were considered significant. Analyses were performed using SAS version 9.2 (SAS Institute, Inc.).
We considered several starting points for our analyses: the date of available radiological diagnosis (which did not differ significantly from the date of clinical onset) and the date of the first treatment. This was done to take into consideration the prognostic factors actually available at these different starting points and the patients who were not treated at the GII stage of their tumor. 24 Last, we analyzed previously reported prognostic scores.
6,14,51
Results
Patient Characteristics
One thousand ninety-seven lesions in 1091 patients constituted this series (Table 1) , for which the mean follow-up was 7.4 years since radiological diagnosis. Four patients had simultaneous bifocal GIIGs, and 1 patient had 3 tumors of similar radiological aspect. The mean age at presentation was 37.6 years, with a large number of pa- 3 (equivalent to a mean diameter of 52 and 54.3 mm), respectively. The main tumor location was frontal. Contrast enhancement was noted in 22.3% of cases, usually faint and patchy (16%), although in 6.3% of cases it was a small nodular, intense enhancement area. Tumor signal appeared more or less heterogeneous in 73.8% and poorly delimited in 60% of cases. Extension of signal abnormality was similar when comparing T1-weighted and T2-weighted/FLAIR images in 73% of the 741 cases in which both sequences were assessable, although it was larger on T2-weighted/FLAIR images in the other cases.
Treatment Options
One hundred sixty-five patients harboring 168 lesions did not receive any oncological treatment at the GII stage of their tumor. Among these cases, 106 were treated when malignant transformation occurred. The other 929 tumors (926 patients) were treated at a mean delay of 30.1 months after onset and 18.7 months after diagnosis. Initial treatment consisted of mostly resection and less often radiotherapy and/or chemotherapy ( Table 2) .
Initial resection (674 cases) reduced the mean tumor volume from 74 to 27.2 cm 3 (mean tumor diameter decreased from 52.9 to 37.9 mm). Complete resection (no residual signal abnormality on postoperative MRI immediately and 2-3 months postoperatively) and subtotal resection (tumor residue < 10 cm 3 ) were achieved in 11.9% (80) and 38.9% (262) of cases, respectively. Twenty-six percent of the patients displayed some degree of immediate postsurgical neurological impairment, but 44.7% and 49.7% of them maintained or recovered a WHO performance status equal to 0 or 1, respectively. The surgeryrelated mortality rate was 0.9%. There were 37 severe complications (6%): wound (1.3%) or pulmonary (0.3%) infection, deficient wound healing (0.5%), epidural hematoma (0.5%), intracerebral hematoma (0.3%), ischemia with new deficits (2.3%), and new seizures (0.8%). Eventually, every case recovered up to a KPS score of at least 60%. Stereotactic biopsy was performed in 272 cases, with no deaths but with a 2.8% morbidity rate (severe morbidity in 1.6% of cases) due to hemorrhage. External irradiation was focal in fractions of 1.8-2 Gy, for a total dose of 40-60 Gy (median 55 Gy, 50-60 Gy in 91.2% of cases). Chemotherapy regimens consisted predominantly of nitrosoureas (7.3%, one-third intraarterially) and procarbazine, lomustine, and vincristine protocol (24.5%) at the beginning of the study and mainly temozolomide (Days 1-5/28-day regimen) in the last decade (75.4%, 1-36 cures, mean 16.6 cures).
Recurrences, Progressions, Anaplastic Transformations, and Survival
During the follow-up, 539 (58%) of the 929 initially treated tumors recurred at least once (Table 3 ). The 286 GII recurrences or progressions were treated once (220 cases), twice (50 cases), or more (16 cases). The mean delay between initial treatment and the first treated GII progression was 42.5 months (median 35 months). During the follow-up period, 466 malignant transformations were observed (Table 4 and Fig. 1) , with one-third initially of the intermediate type. Of these 466 transformations, 462 were treated at least once. In 220 cases, 1-4 additional treatments were administered. Treatments for all initial and subsequent malignant transformations consisted of surgery in 41.1% of cases, radiotherapy in 48.8%, and chemotherapy in 86.3%.
During the follow-up, 245 deaths were observed at a mean delay of 7.7 years after diagnosis (Fig. 1) . Observed deaths occurred at a mean delay of 2.1 years after radiological evidence of malignant transformation, 3.1 years for the intermediate forms and 1.85 years for the anaplastic forms. The mean observed survival in the 847 patients alive at the last follow-up since diagnosis was 6.6 years (median 5.3 years) and was 5.4 years (median 4.4 years) after eventual initial treatment in 707 cases.
Results of Statistical Analysis
Considering the entire series at time of radiological diagnosis (Table 5) , a priori independent prognostic factors were patient age (cutoff 54 years; Fig. 2 ), sex (female), tumor size (Fig. 3) and location (frontal vs temporal vs other sites; Fig. 4) , and KPS score. Other clinicoradiological parameters, such as neurological deficit, number of lobes involved, MRI tumor delineation, and mass effect, were significant on univariate analysis only. Considering only treated cases at the time of initial treatment, independent factors were tumor size, presence of epilepsy, and extent of resection (Fig. 5) . After completion of the initial treatment, prognostic factors were tumor size (after initial resection if performed), tumor location, patient age (older than 54 years), and subsequent resection (subsequent chemotherapy was not retained in the model). In this series, chemotherapy and radiotherapy did not significantly influence survival. Survival curves according to several previously reported prognostic scores combining several prognostic parameters are shown in Fig. 6 .
Discussion
We reviewed the cumulated experience from the MRI era in a multicenter group with WHO GIIGs, ensuring homogeneous data collection. To our knowledge, ours is the largest series of supratentorial hemispheric GIIGs in adults for which volumetric assessment was available before any oncological treatment and after initial surgery if any. The overall median survival (close to 15 years since initial diagnosis) is in good agreement with rates in recently reported studies. 43, 65 Malignant transformation represents the principal lethal factor in these patients, 19 as confirmed by the parallel linearity of the survival and anaplastic curves in our series (Fig. 1) . This observation validates the emerging view 40 that malignant progressiondefined either radiologically or histologically-represents a relevant end point when designing clinical trials.
Flaws and Biases of the Study
The epidemiological characteristics of this series did not differ from those in other series of GIIGs reported in the literature. 33, 36, 44, 45, 60, 64 Despite our efforts, this study was subject to already-mentioned biases and drawbacks inherent to this pathology, which needs successive and individually adapted treatments of different modalities. Still, our results are reliable because the mean and median follow-ups encompassed the delays of observed anaplastic transformations and were close to those of observed deaths. Furthermore, survival curves were linear, making it very unlikely that they could dramatically change. 28 In addition, 21.3% of patients were still at risk 10 years after radiological diagnosis. Finally, even though this series covered a long period and different centers, the results in terms of prognostic factors were similar along time and among the 6 academic centers representing the core of the study group.
Spontaneous Prognostic Factors
Consistent with the literature, our study confirmed that tumor size and location, neurological symptoms and status, and patient age are strong prognostic factors.
Tumor Size. The relation between tumor size and survival has been described in several GIIG series.
9,14,36,51,61
Mass effect, focal deficits, and/or intracranial hypertension leading to a poorer functional status are significant factors on univariate analysis but not on multivariate analysis, probably because they are related to tumor volume. Moreover, a larger tumor size hampers therapeutic possibilities. 26, 65 Complete resection of large tumors is seldom feasible because they are more likely to extend into eloquent areas.
14 In our study, the possibility and extent of resection were correlated with pretreatment tumor size, especially for lesions over 40 mm in mean diameter. We estimated tumor volume using ellipsoid approximation after measuring the 3 maximal orthogonal tumor diameters, 68 because it could be performed for all patients and DICOM images were not available for early patients. Although this method is less accurate than segmentation and more subject to overestimation, a random review of 25% of the cases by another observer suggested that interobserver discrepancy was low (data not shown).
Clinical Status. The clinical and neurological status before and/or after an oncological treatment classically influences survival. 31, 34, 36, 67 The presence of a neurological deficit increases with age, tumor extension, and mass effect. 35 At the time of diagnosis, the existence of epilepsy is inversely linked to the presence of a deficit and consequently carries a favorable prognostic value when isolated.
51,70
Age. Patient age is a well-known prognostic factor. 6, 14, 51 In our series, disease in the patients in the 3 most represented decades behaved somewhat similarly. In contrast, patients whose clinical history had begun before they were 20 years old often had a long indolent course of the disease, 22, 32 suggesting a similarity with dysembryoplastic neuroepithelial tumors 4 or cortically based tumors of different origin. 50 Patients older than 54 years of age tended to have a shorter survival. 6, 36, 51, 60, 61 These considerations suggest that a cutoff around 40 years of age, as is often discussed in the literature or even used in trials, is not optimal.
Tumor Location. Frontal and parietal tumor locations classically carry a better prognosis than other locations, which is not entirely explained by the possibility of better resection. A frontal location may be related to biological- * FU = follow-up; NA = not applicable. † Encompasses all cases in series, including those not treated at the GII stage that eventually showed up later on anaplastic transformation. ‡ Cases treated initially at the GII stage (as in Table 1 ).
ly favorable prognostic factors such as oligodendroglioma subtype 29 and 1p and 19q deletions.
30
Contrast Enhancement. Some degree of contrast enhancement was present in 22.3% of our cases, which is concordant with the literature (8%-36% according to another series 46 ). Contrast enhancement was not a statistically significant prognostic factor even at the univariate level. Actually, qualitative and pathological assessment of contrast enhancement is important: whereas faint and patchy contrast enhancement does not carry a prognostic value, 11,34,46,61 nodular or progressive contrast enhancement is related to a bad prognosis.
16,46
Histological Oncotype. Histological oncotype did not influence outcome in our patients. Moreover, the determination of glioma oncotype remains difficult, controversial, and carries poor interobserver consistency, 23 which makes this criterion difficult to use as a reliable prognostic factor. However, estimation of tumor aggressiveness is a key point, especially in the absence of contrast enhancement. In this context, assessment of microfoci of anaplasia and biomarkers will have to be considered in future studies.
Prognostic Scores. World Health Organization GIIGs represent an ever-changing tumor in its geno-/phenotype along a continuum, with grossly 2 clinicoradiological phases, 12 from a truly indolent tumor to a malignant form, with a usually gradual transition.
10 This view is supported by the observation that incidentally discovered GIIGs become symptomatic with time, 47 that patients with initial wait-and-see management 41, 48 exhibit continuous growth and clinical worsening, and that molecular data show the accumulation of genetic and molecular abnormalities with time. 57, 71 The incidence of malignant transformation increases with time, with each recurrence, 1 and thus with the duration of follow-up. 53 The ideal prognostic factors should be able to identify the stage at which a given tumor is encountered during its natural history and, in particular, to predict the time of malignant transformation.
Two previously reported scores, derived from recursive partitioning analysis 6 and the EORTC trials, 51 seem to be of limited value when applied to our series (Fig. 6) . In both classifications, only 12% and 9% of the patients could be segregated in the worse prognostic groups. On the contrary, our series validates the scoring system recently proposed by the University of California, San Fran- cisco, team, 14 distinguishing 3 prognostic groups of notable importance (49.7%, 34.7%, and 15.6% of our cases).
Therapeutic Prognostic Factors
Surgery. Given the unreliability of the surgeon's impression, 63 the objective evaluation of pre-and postoperative tumor volumes is mandatory to ascertain the role of resection. Note that resection was the only independent therapeutic prognostic factor verified in our study.
When the quality of resection has been quantitatively analyzed on postoperative MRI, whatever the assessment method, it has been of prognostic significance most of the time (see reviews 24, 58 ). The best outcomes were obtained, as in our series, when a complete radiological resection could be performed. 9, 63 We deliberately considered very stringent criteria to define complete resection on postoperative MRI. Consequently, the proportion of complete resections was relatively low, but we observed no recurring signal abnormality for at least 4 years after a radiologically complete resection, and recurrences were essentially of the GII type. Moreover, the occurrence of anaplastic transformation was delayed after subtotal resection. Hence, subtotal, and above all radiologically complete, resection significantly influenced survival, probably by delaying anaplastic transformation. The quality of resection may also influence functional and epileptic outcomes. 13, 20 Our mortality and morbidity rates were 1% and 6%, respectively. In the most recent period, as experience with and use of direct cerebral electrical stimulation increased, permanent severe deficits became very rare, while the proportion of possible complete or subtotal resections increased, even in eloquent areas.
18,25
Radiotherapy. In our series, the use of radiotherapy at the GII stage, whether early or delayed and whatever its dose, did not significantly influence overall survival. This result was in accordance with prospective trials that have shown that radiotherapy does not influence overall survival but can prolong progression-free survival 7, 8, 27, 38, 62, 69 and may improve clinical symptoms.
27
Chemotherapy. In our series, chemotherapy adminis- tered at the GII stage did not significantly influence survival despite a positive trend, although it seemed to select long-term survivors. However, chemotherapy regimens were heterogeneous, and chemotherapy was administered more frequently in patients with unfavorable prognostic factors (large and deep-seated tumors, neurological deficit, or absence of resection), which represent sources of bias.
Treatment of Recurrences.
In this series, the resection of GII recurrences significantly influenced survival on multivariate analysis, as already suggested. 2 In the absence of definitely curative treatment, reducing tumor growth and volume as often as possible seemed, in our series, to prolong survival. Hence, we advocate the use of aggressive treatments, repeated and combined over time if possible, during the GII stage of glioma evolution, because their benefits seem to outweigh their risks. Moreover, subsequent surgeries allow one to update the pathological evaluation and consequently to offer opportunities to deliver adjuvant therapies earlier in cases of microscopic focal signs of anaplasia.
Conclusions
Our study highlights the fact that spontaneous prognostic factors have the greatest influence on the survival expectancy of adults harboring GIIGs, since they reflect the innate biological behavior of the tumor, its interaction with its host, and the stage at which an ever-evolving tumor is discovered. Although long the subject of controversy, when the extent of resection is objectively assessed by measuring pre-and postoperative tumor volumes, surgery has a strong favorable impact on survival, especially if resection is complete on postoperative MRI. The decision to perform surgery should be made early in the visible course of these tumors, before any truly disturbing symptom to prevent further tumor growth and to optimize the benefit/risk ratio. This therapeutic strategy-repeated as much as possible, associated with close peri-and intraoperative anatomofunctional and biological monitoring, and helped by the phenomenon of cerebral plasticity over time 17 -appears to prolong overall survival. 
C:
Survival according to the Chang scoring system.
14 The x axes represent the duration of follow-up in months; the y axes, the percentage of patients (1 = 100%).
